PE20141945A1 - Derivados de quinolina como inhibidores de la enzima pde10a - Google Patents

Derivados de quinolina como inhibidores de la enzima pde10a

Info

Publication number
PE20141945A1
PE20141945A1 PE2014000989A PE2014000989A PE20141945A1 PE 20141945 A1 PE20141945 A1 PE 20141945A1 PE 2014000989 A PE2014000989 A PE 2014000989A PE 2014000989 A PE2014000989 A PE 2014000989A PE 20141945 A1 PE20141945 A1 PE 20141945A1
Authority
PE
Peru
Prior art keywords
inhibitors
quinoline
pde10a enzyme
quinoline derivatives
compounds
Prior art date
Application number
PE2014000989A
Other languages
English (en)
Inventor
Jan Kehler
Jacob Nielsen
Ask Puschl
John Paul Kilburn
Morten Langgard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48667762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141945(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of PE20141945A1 publication Critical patent/PE20141945A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE QUINOLINA DE FORMULA (I) DONDE R1, R2, R3, R4, R5 Y R6 SON CADA UNO H, HIDROXILO, CN, ALCOXI(C1-C6), ENTRE OTROS; L ES UN CONECTOR TAL COMO -CH2-CH2- O -CH=CH-; HET ES UN COMPUESTO DE FORMULA (i), (ii), ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS. SON COMPUESTOS PREFERIDOS: 2-[(E)-2-(5,8-DIMETIL-[1,2,4]TRIAZOLO[1,5-a]PIRAZIN-2-IL)-VINIL]-6-TRIFLUOROMETIL-QUINOLINA; 6-[2-(5,8-DIMETIL-[1,2,4]TRIAZOLO[1,5-a]PIRAZIN-2-IL)-ETIL]-1,3-DIOXOLO[4,5-g]QUINOLINA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA PDE10A SIENDO UTILES EN EL TRATAMIENTO DE TRANSTORNOS PSIQUIATRICOS O NEURODEGENERATIVOS
PE2014000989A 2011-12-21 2012-12-21 Derivados de quinolina como inhibidores de la enzima pde10a PE20141945A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201100990 2011-12-21

Publications (1)

Publication Number Publication Date
PE20141945A1 true PE20141945A1 (es) 2014-12-18

Family

ID=48667762

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000989A PE20141945A1 (es) 2011-12-21 2012-12-21 Derivados de quinolina como inhibidores de la enzima pde10a

Country Status (32)

Country Link
US (2) US9216986B1 (es)
EP (1) EP2794606A1 (es)
JP (1) JP6073918B2 (es)
KR (1) KR20140105574A (es)
CN (1) CN104114554A (es)
AP (1) AP2014007697A0 (es)
AR (1) AR089361A1 (es)
AU (1) AU2012356885B2 (es)
BR (1) BR112014015192A8 (es)
CA (1) CA2859702A1 (es)
CL (1) CL2014001643A1 (es)
CO (1) CO6990727A2 (es)
CR (1) CR20140289A (es)
DO (1) DOP2014000141A (es)
EA (1) EA028824B1 (es)
EC (1) ECSP14010000A (es)
GE (1) GEP201706657B (es)
HK (1) HK1202861A1 (es)
IL (1) IL233226A (es)
MA (1) MA35860B1 (es)
MD (1) MD20140070A2 (es)
MX (1) MX348792B (es)
MY (1) MY165216A (es)
PE (1) PE20141945A1 (es)
PH (1) PH12014501434A1 (es)
RU (1) RU2624440C2 (es)
SG (1) SG11201403339YA (es)
TN (1) TN2014000268A1 (es)
TW (1) TWI570124B (es)
UA (1) UA111871C2 (es)
WO (1) WO2013092974A1 (es)
ZA (1) ZA201404533B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR089361A1 (es) 2011-12-21 2014-08-20 Lundbeck & Co As H Derivados de quinolina como inhibidores de la enzima pde10a
CA2889906A1 (en) * 2012-11-29 2014-06-05 Sunovion Pharmaceuticals Inc. Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
US20070105840A1 (en) 2003-06-30 2007-05-10 Altana Pharma Ag Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
AU2004253694A1 (en) 2003-06-30 2005-01-13 4Sc Ag Novel pyrrolodihydroisoquinolines useful in the treatment of cancer
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
CA2556413A1 (en) 2004-02-18 2005-09-09 Pfizer Products Inc. Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
EP1755611A1 (en) 2004-06-07 2007-02-28 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
AU2005282721A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
EP2565191B1 (en) 2008-05-14 2014-10-08 Astellas Pharma Inc. 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
JP2011201873A (ja) * 2010-03-03 2011-10-13 Mitsubishi Tanabe Pharma Corp 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用
CN103038229B (zh) * 2010-05-26 2016-05-11 桑诺维恩药品公司 杂芳基化合物及其使用方法
AR089361A1 (es) 2011-12-21 2014-08-20 Lundbeck & Co As H Derivados de quinolina como inhibidores de la enzima pde10a

Also Published As

Publication number Publication date
AU2012356885B2 (en) 2016-09-08
HK1202861A1 (en) 2015-10-09
MY165216A (en) 2018-03-09
MX348792B (es) 2017-06-29
EA201491152A1 (ru) 2015-01-30
CL2014001643A1 (es) 2014-11-21
GEP201706657B (en) 2017-04-25
PH12014501434B1 (en) 2014-09-22
BR112014015192A2 (pt) 2017-06-13
IL233226A0 (en) 2014-08-31
ECSP14010000A (es) 2015-12-31
CR20140289A (es) 2014-08-18
IL233226A (en) 2017-11-30
DOP2014000141A (es) 2014-07-31
EP2794606A1 (en) 2014-10-29
RU2014127984A (ru) 2016-02-10
AU2012356885A1 (en) 2014-07-10
CN104114554A (zh) 2014-10-22
US9216986B1 (en) 2015-12-22
RU2624440C2 (ru) 2017-07-04
US9801878B2 (en) 2017-10-31
KR20140105574A (ko) 2014-09-01
SG11201403339YA (en) 2014-07-30
US20160303120A1 (en) 2016-10-20
AP2014007697A0 (en) 2014-06-30
TN2014000268A1 (en) 2015-09-30
MX2014007409A (es) 2014-08-01
UA111871C2 (uk) 2016-06-24
CO6990727A2 (es) 2014-07-10
NZ626279A (en) 2015-07-31
JP2015502970A (ja) 2015-01-29
MA35860B1 (fr) 2014-12-01
ZA201404533B (en) 2015-12-23
WO2013092974A1 (en) 2013-06-27
CA2859702A1 (en) 2013-06-27
EA028824B1 (ru) 2018-01-31
BR112014015192A8 (pt) 2017-06-13
MD20140070A2 (ro) 2014-12-31
TWI570124B (zh) 2017-02-11
US20150376186A1 (en) 2015-12-31
AR089361A1 (es) 2014-08-20
JP6073918B2 (ja) 2017-02-01
PH12014501434A1 (en) 2014-09-22
TW201339156A (zh) 2013-10-01

Similar Documents

Publication Publication Date Title
MD20140130A2 (ro) 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
MY170326A (en) Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors
PH12014501695A1 (en) Pde9 inhibitors with imidazo triazinone backbone
TN2013000394A1 (fr) Derives de pyrrolo [2,3-d] pyrimidine servant d'inhibiteurs de kinases apparentees a la tropomyosine
NZ708864A (en) Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
PE20130457A1 (es) INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT
PE20161552A1 (es) Compuestos de dihidroisoquinolinona sustituida
PE20071104A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv (dpp-4)
MX2015004422A (es) Pde9i con estructura principal de imidazopirazinona.
PE20121438A1 (es) Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a
MX2010007714A (es) Piridinas fusionadas activas como inhibidores de c-met.
PE20110545A1 (es) Compuestos de triazolopiridina como inhibidores de jak
NZ630721A (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
UA107952C2 (uk) ПОХІДНІ ІМІДАЗО[1,2-a]ПІРАЗИНУ І ЇХ ЗАСТОСУВАННЯ ДЛЯ ПРОФІЛАКТИКИ АБО ЛІКУВАННЯ НЕВРОЛОГІЧНИХ, ПСИХІАТРИЧНИХ І МЕТАБОЛІЧНИХ РОЗЛАДІВ І ЗАХВОРЮВАНЬ
PE20130376A1 (es) [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer
NZ600430A (en) Spiro-oxindole mdm2 antagonists
NZ626394A (en) Substituted annulated pyrimidines and triazines, and use thereof
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
PE20140970A1 (es) Derivados de 6-ciclobutil-1,5-dihidro-pirazol [3,4-d) pirimidin-4-ona y su uso como inhibidores de pde9a
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
PE20141351A1 (es) Triazolopiridinas
CL2011001152A1 (es) Compuesto cristalino 6-((s)-1-(6-(1-metil-1h-pirazol-4-il)-[1,2,4]triazolo[3,4-b][1,3,4]tiadiazol-3-il)etil)quinolina, inhibidor de la proteina kinasa c-met; composicion farmaceutica; y metodo para tratar o disminuir la gravedad de un trastorno proliferativo tal como cancer metastasico de colon, mama y hepatico, entre otros.
PE20130346A1 (es) Compuestos heterociclicos fusionados
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
MY184858A (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed